Juvenile myelomonocytic leukemia (JMML) is a malignant hematopoietic disorder of early childhood with excessive proliferation of the myeloid and monocytic lineage. Deregulation of the RAS signal transduction pathway is thought to play a key role in its pathogenesis. We examined peripheral blood or bone marrow cells of 36 children with JMML for activating point mutations in codons 12, 13 and 61 of the NRAS and KRAS proto-oncogenes by allele-specific restriction assay, singlestrand conformation polymorphism and/or direct sequencing. Codons 12, 13 and 61 of HRAS were examined in 26 of these patients. We detected RAS mutations in six cases (17%) located at N12 (n = 2), N13 (n = 3) and K13 (n = 1). In addition, we performed clonality studies on different cell lineages in four of these patients applying the RAS mutation, the karyotype and X-chromosome inactivation patterns as clonal markers. Erythroid cells carried mutant RAS, indicating clonal origin. In EBV B cell lines, one of three patients studied harbored a RAS mutation, while the other two patients had polyclonal B cells with wildtype RAS. T lymphocytes were examined in one patient; they were polyclonal and had wild-type RAS. It is likely that JMML is a heterogeneous disease with respect to clonal involvement of different lineages.
Introduction
Juvenile myelomonocytic leukemia (JMML) is a hematopoietic malignancy of childhood characterized by prominent hepatosplenomegaly, frequent skin involvement, leukocytosis, monocytosis and the presence of immature precursors in peripheral blood (PB). 1, 2 Its annual incidence is about 1.3/million children. 3 The disorder has also been referred to as 'juvenile chronic myelogenous leukemia' (JCML) or 'chronic myelomonocytic leukemia in childhood' (CMML). 1 JMML is a clonal disorder as assessed by X-chromosome inactivation studies. 4 Hematopoiesis in JMML features an excessive proliferation of myeloid progenitor cells and a specific hypersensitivity for GM-CSF in vitro. 5 Because stimulation with GM-CSF is known to be associated with RAS activation, 6 mutations resulting in a deregulated RAS pathway are of particular interest in JMML.
p21RAS is a family of guanine nucleotide binding proteins located at the inner cell membrane which forward stimuli for cell proliferation and differentiation to the nucleus through a kinase cascade. 7 The RAS proteins cycle between an active, GTP-bound conformation and an inactive, GDP-bound form. 8 GTPase-activating proteins (GAPs) negatively regulate the signal output of RAS proteins by accelerating GTP hydrolysis. 9 Several GAPs connected with RAS proteins have been identified, including neurofibromin, the product of the neurofibromatosis type 1 (NF 1) tumor suppressor gene (NF1). NF1 is clinically diagnosed in about 15% of children with JMML. 1 In addition, truncating NF1 mutations can be shown in a proportion of children with JMML without clinical evidence of NF1. 10 While NF1 −/− knock-out mice die in utero at an embryonic stage, cultured fetal NF1 −/− hematopoietic cells demonstrate a pattern of selective hypersensitivity to GM-CSF. 11, 12 Like decreased GAP activity, specific point mutations of the RAS genes can result in persistent activation of the RAS signaling pathway. 13 In this study, we wanted to determine the frequency of point mutations at codons 12, 13 or 61 of the NRAS, KRAS or HRAS genes in a large cohort of children with JMML. In addition, mutant RAS genes, karyotype analysis and, in female patients, X-chromosome inactivation clonality assays were used as markers for clonal involvement of different cell lineages in JMML patients.
Materials and methods

Patients
Thirty-six children with JMML were studied. Clinical data are given in Table 1 . NF1 was known in three patients. Chromosomal analyses in leukemic cells were available in 32 of the 36 children and showed a normal karyotype in 23 children, monosomy 7 in four children and complex aberrations in five children.
Cell cultures
Adherence depleted mononuclear cells (MNC) from PB were cultured in a serum-deprived semi-solid methylcellulose system 14 at 5 × 10 4 cells/ml in the presence of erythropoietin (2 U/ml). After 14 days of culture at 37°C in a 4% CO 2 atmosphere, colonies derived from erythroid burst-forming units (BFU-E) were harvested. EBV transformed B lymphocytes were grown in RPMI 1640 (Gibco, Eggenstein, Germany) supplemented with 10% fetal calf serum (FCS), 2 mm l-glutamine, 100 U/ml penicillin/streptomycin. 15 
Fluorescence-activated cell sorting (FACS)
After lysis of erythrocytes, PB cells were maintained in RPMI 1640/10% FCS. Per 10 6 cells, 10 l phycoerythrin-conjugated monoclonal anti-CD3 (Laboserv, Giessen, Germany) was added. Cells were incubated for 15 min, washed twice and sorted on a FACStar Plus (Becton Dickinson, Heidelberg, Germany). The purity of CD3
+ cells was greater than 90%. WBC, white blood count; HbF, fetal hemoglobin; −7, monosomy 7; 7q−, deletion on long arm of chromosome 7; ND, no data available. Survival is given in years after diagnosis; +, patient alive; BMT, bone marrow transplantation. Spleen and liver size are given in cm below costal margin; *, enlarged (size below costal margin not evaluated).
DNA preparation
In 13 cases, DNA was extracted from total bone marrow (BM) (n = 3) or PB (n = 10) cells. In 24 cases, cell populations from PB (n = 13) or BM (n = 11) were separated on a Ficoll density gradient (Pharmacia, Freiburg, Germany). DNA was extracted from MNC (above the Ficoll fraction) (n = 4) and myeloid cells (below the Ficoll fraction, on top of red cells) (n = 20). DNA preparation followed a standard protocol. 16 
PCR amplification
For allele-specific restriction analyses (ASRA), one PCR primer of each pair was designed to contain one or more base mismatches adjacent to the codon of interest, creating a restriction site in wild-type, but not in mutant fragments. 17 For single-strand conformation polymorphism (SSCP) analyses, fully matched primers were used. The opposite primer of each pair was placed into intron sequences to avoid pseudogene amplification. Primer sequences, thermal cycling conditions and restriction enzymes used will be provided to interested researchers upon request. DNA from THP-1 cells (point mutation at codon 12 of NRAS) 18 and from RC2A cells (point mutation at codon 12 of KRAS) 19 served as positive controls. K562 cells were used as negative control. 17 
Mutation analysis
Two different methods were used for the identification of RAS mutations: ASRA (n = 26) and SSCP (n = 10). For ASRA, restriction digests were incubated in 20 l reaction buffer (as provided by the enzyme manufacturer) containing 3-7 l PCR product (depending on DNA content as estimated by band intensity on the gel) and 4-10 U of restriction endonuclease (New England Biolabs, Schwalbach, Germany) for 3 h at the appropriate temperature. To ensure complete digestion, each assay was subjected to a second incubation with fresh enzyme. The fragments were separated on 7-12% polyacrylamide gels. SSCP analyses were performed according to the method previously described by Orita et al. 20 1 l of the amplified PCR product was subjected to 18 additional cycles of PCR in a 25 l solution containing 200 mol/l dATP, dGTP and dTTP and 1 l 32 PdCTP (Amersham, Buckinghamshire, UK) in addition to the reagents used for the first PCR. Gels were run at 4°C.
Direct sequencing
If a putative mutation was seen in ASRA or SSCP, direct sequencing was performed to define the base exchange and exclude false-positive results. Sequence analysis without prior ASRA or SSCP was used for NRAS codon 61 in 26 cases, KRAS codons 12 and 13 in 11 cases and KRAS codon 61 in 37 cases. The dideoxynucleotide chain termination method was performed using digoxigenin-labeled primers (MWG Biotech, Ebersberg, Germany) and a cycle sequencing kit (Thermo Sequenase; Amersham). After ethanol precipitation, 2 l PCR product was added to 1 nmol primer in a total volume of 8 l Sequenase reaction mix. Sequencing primers were: 5Ј-AGGATCAGGTCAGCGGGCTACCACT for NRAS codons 12/13; 5Ј-CCTCTATDGTKGGGTCATATTC for KRAS codons 12/13 (K = wobble G/T, D = wobble A/G/T; this primer was intended for use with all three RAS genes); 5Ј TTGGCAAT-AGCATTGCATTCCCTGT for NRAS codon 61; and 5Ј-TGTTGTTGAGTTGTATATAACACCT for KRAS codon 61. Thermal conditions were: initial denaturing (95°C; 3 min) and 30 cycles of primer annealing (60°C; 1 min) and denaturing (95°C; 1 min). Reaction products were separated on 5% polyacrylamide gels, directly blotted on to a nylon membrane, and visualized using alkaline phosphatase-conjugated anti-digoxigenin and a detection kit based on a NBT 2 /X-phosphate color reaction (Boehringer, Mannheim, Germany).
Human androgen receptor gene (HUMARA) clonality assay
The HUMARA assay was performed in two female patients as previously described. 21 
Fluorescence in situ hybridization (FISH)
The repetitive alphoid probe p7t1 22 was used after nick translation with biotin-16-dUTP. Preparations were pretreated with RNase, washed in SSC and dehydrated in a graded ethanol series. After probe and target DNA denaturation hybridization (20 h) was performed with a mixture containing 60% formamide, 2 × SSC; 5% dextran sulfate, 500 g/ml salmon sperm DNA and 2 g/ml DNA probe. The reaction was visualized using an avidin-conjugated fluorescein isothiocyanate (FITC) vector. 23 Amplification was done with additional layers of biotinylated goat anti-avidin and avidin-FITC. Signal evaluation followed the criteria published by Hopman et al. 24 From each specimen 500 nuclei were scored.
Gene sequence data
Information on human gene sequences was obtained from EMBL database, Heidelberg, Germany. Sequence information on the 3Ј terminus of NRAS intron 2 came from a previous cloning experiment.
Results
Point mutations in codons 12, 13 or 61 of the RAS genes were detected in six of the 36 (17%) children with JMML. Three children with RAS mutations were girls, and three were boys. Because the three children with JMML and NF1 had wild-type RAS genes, the frequency of RAS mutations among children with JMML without the clinical diagnosis of NF1 was six of 33 (18%). Two children had a mutation in codon 12 of NRAS, three children in codon 13 of NRAS, and one child in codon 13 of KRAS. None of the 26 patients analyzed had a mutation in one of the three HRAS codons studied. Of the six children with RAS mutations, five had a normal karyotype and one (patient 25) had monosomy 7.
The RAS mutations identified provided an opportunity to investigate the clonal derivation of different lineages. The erythroid lineage was analyzed in two patients. Point mutations detected in PB myeloid cells were also present in erythroid cells of BFU-E derived colonies ( Table 2 ). In concordance with this finding, erythroid cells from one of the two patients studied were clonally derived by X-chromosome inactivation studies ( Table 2 ). The involvement of the lymphoid lineage was assessed in three patients. In patient 20 (mutation at NRAS 12), EBV-transformed B cells showed wildtype RAS. In concordance, the HUMARA assay demonstrated clonal involvement of granulocytes, but not of EBV B cells (Table 2) . From patient 25 (mutation at KRAS 13), EBV-transformed B lymphocytes, sorted CD 3+ T lymphocytes and CD3 − cells (a mixture of granulocytes and MNC) were analyzed. While mutant RAS was seen in CD3 − cells, RAS was normal in B and T lymphocytes (Figure 1) . On a cytogenetic level, FISH analyses confirmed monosomy 7 in CD3 − cells and demonstrated disomy 7 in CD3 + lymphocytes and in the EBVtransformed B cell line (data not shown). These results were consistent with the HUMARA assay which showed polyclonal derivation of CD3 + T lymphocytes and EBV-transformed B lymphocytes (Table 2) . Thus, in patients 20 and 25, lymphoid cells were not part of the leukemic clone. In contrast, EBVtransformed B lymphocytes of patient 35 (mutation at NRAS 13) harbored the same RAS mutation that had previously been demonstrated in unfractionated cell lysates.
While in five patients the RAS mutations were presented at the time of diagnosis, hematopoietic cells of patient 20 acquired the mutation during the clinical course. The girl presented at the age of 4.8 years with severe thrombocytopenia without hepatosplenomegaly, monocytosis or spontaneous growth of myeloid progenitors. There was no RAS mutation in PB myeloid cells. The child was seen again 1.5 years later with a clinical and hematological picture characteristic of JMML. She had developed leukocytosis, monocytosis and a marked enlargement of liver and spleen. Spontaneous growth of myeloid progenitors was present. A nucleotide substitution at codon 12 of NRAS was detectable in PB myeloid cells, but was absent in EBV-transformed B cells.
Discussion
In this study we detected RAS mutations in six of 33 (18%) children with JMML without clinical evidence of NF1. These results are in agreement with findings by Kalra et al 25 who reported mutant N-or KRAS in the absence of NF1 in five of 24 (20%) patients classified as JCML and four of 27 (15%) patients classified as monosomy 7 syndrome (some of which had clinical features of JMML). In a study by Sheng et al,
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Figure 1
Allele-specific restriction analysis of RAS mutations in different hematopoietic cell lineages of patient 25 (KRAS codon 13: GGC→GAC). The 161 bp band represents normal RAS alleles. The 187 bp band represents mutant RAS alleles. Lanes: M, 187 bp standard; 1, wild-type control; 2, granulocytes; 3, BFU-E-derived colonies; 4, CD3 + cells; 5, CD3 − cells; 6, EBV-transformed B cells. RAS mutations were found in one of 12 (8%) children with JMML. In contrast to these data, Miyauchi et al 27 examining NRAS only detected mutations in 30% (6/20) of JMML patients. In our cohort, there was a predominance of mutant NRAS (n = 5) over KRAS (n = 1), while the distribution was equal in the study by Kalra et al. In both studies, all mutations were restricted to codons 12 and 13 of the first coding exons. Although HRAS mutations have been described in adults with CMML, 28 we did not detect mutations in HRAS codons 12, 13 and 61 in 26 patients studied.
We conclude that the frequency of mutations of the RAS gene in children with JMML without NF1 is about 20% irrespective of karyotype. NF1 and RAS mutations appear to be mutually exclusive 25 as no patient with NF1 and concomitant RAS mutation has been identified. Considering that about 15% of children with JMML have NF1, 1 and about 15% without clinical evidence of NF1 have truncating mutations of the NF1 gene, 10 50% of children with JMML have evidence of activation of the RAS signaling pathway by RAS or NF1 mutations. One might speculate that the remaining 50% have abnormalities in the RAS pathway that are yet to be defined.
So far, we have investigated two candidate genes, HCP and SHC, and found normal expression in hematopoietic cells of JMML patients (unpublished work).
One patient in our cohort had normal RAS at the time of first clinical presentation but showed a point mutation in NRAS 1.5 years later when the clinical picture was characteristic of JMML. The appearance of new RAS mutations during the course of myelodysplastic syndromes has also been observed by others. [29] [30] [31] The formation of the aberrant clone and the deregulation of the RAS pathway may constitute two different steps in leukemogenesis. It is tempting to speculate that activation of the RAS pathway is a prerequisite for the JMML phenotype. This view is supported by experiments showing that sublethally irradiated mice reconstituted with Nf1-deficient hematopoietic liver cells consistently develop a myeloproliferative disorder similar to JMML. 12 The erythroid lineage carried the same RAS alteration as the respective myeloid cells, confirming the clonal origin of erythropoiesis in JMML. 4, 32, 33 In two of the three patients with EBV B cell lines studied, B lymphocytes had wild-type RAS and -in the case of the patient with monosomy 7 -normal karyotype. Like EBV B cells, CD3
+ T lymphocytes carried wild-type RAS and polyclonality of B and T lymphocytes was confirmed by X-chromosome inactivation analysis. These data are in agreement with previous reports of non-leukemic T and B lymphocytes in JMML as assessed in mitogen-stimulated lymphocytes and EBV-transformed B cells by analysis of RAS mutations or loss of heterozygosity for NF1. 33, 34 In contrast, one of our patients demonstrated a clonal RAS mutation in EBV-transformed B cells (patient 35). This child had typical clinical features of JMML. Clonal derivation of lymphocytes in JMML has also been suggested by X-chromosome inactivation analysis in one report, 4 although definitive purification of lymphocyte subsets had not been performed. Miles et al 33 reported a child with NF1 with an unusual myeloproliferative syndrome which showed clonal involvement of EBV-transformed cells as assessed by NF1 allelic loss. In addition, two cases of JMML evolving into B lymphoid blast crisis have been reported. 35, 36 A study of immunoglobulin heavy chain gene rearrangements also supported clonal derivation of B lymphoblasts in some patients. 37 Taken together, these data suggest that in JMML the clonal involvement of cells of the lymphoid lineage, in particular B lymphocytes, is heterogeneous.
